3 September 2020 - Knight Therapeutics Inc. announced filing of the supplement to a new drug submission (SNDS) of Nerlynx for HER2-positive metastatic breast cancer in Canada.

The SNDS is supported by the results of the Phase III NALA trial, a randomized controlled trial of neratinib plus capecitabine versus Tykerb (lapatinib) plus capecitabine in HER2-positive metastatic breast cancer patients previously treated with = 2 HER2-directed regimens.

Read Knight Therapeutics press release.